Abstracts tagged "human leukocyte antigens (HLA) and systemic sclerosis"

Abstract Number: 1962 • 2018 ACR/ARHP Annual Meeting
HLA Contributions to Risk and Protection for Anti-Centromere Autoantibody-Positive Scleroderma
Elaine F. Remmers¹, Theresa Alexander², Nadia D. Morgan³, Ami A. Shah⁴, Maureen D. Mayes⁵, Adebowale Adeyemo¹, Ayo Doumatey¹, Amy Bentley¹, Daniel Shriner⁶, Settara C Chandrasekharappa¹, Mary A. Carns⁷, Lorinda Chung⁸, Lindsey A. Criswell⁹, Chris T. Derk¹⁰, Robyn T. Domsic¹¹, Heather Gladue¹², Avram Goldberg¹³, Jessica K. Gordon¹⁴, Vivien Hsu¹⁵, Reem Jan¹⁶, Dinesh Khanna¹⁷, Thomas A. Medsger Jr.¹⁸, Paula S. Ramos¹⁹, Marcin A. Trojanowski²⁰, Lesley Ann Saketkoo²¹, Elena Schiopu²², Victoria Shanmugam²³, Benjamin D. Korman²⁴, Brynn Kron⁹, S. Louis Bridges Jr.²⁵, Kathleen D. Kolstad²⁶, Elana J. Bernstein²⁷, Suzanne Kafaja²⁸, Kathleen Maksimowicz-McKinnon²⁹, Rick Silver³⁰, Virginia D. Steen³¹, John Varga³², Charles Rotimi¹, Francesco Boin³³, Fredrick M. Wigley³⁴, Daniel L. Kastner³⁵ and Pravitt Gourh³⁶, ¹National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ²National Institutes of Health, Bethesda, MD, ³Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Rheumatology, University of Texas McGovern Medical School, Houston, TX, ⁶National Human Genome Research Institute, National Institutes of Health (NIH), Bethesda, MD, ⁷Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL, ⁸Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA, ⁹University of California San Francisco, San Francisco, CA, ¹⁰Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹¹Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ¹²Rheumatology, Arthritis and Osteoporosis Consultants of the Carolinas, Charlotte, NC, ¹³NYU Langone Medical Center, New York, NY, ¹⁴Rheumatology, Hospital for Special Surgery, New York, NY, ¹⁵Rheumatology, Robert Wood Johnson University Scleroderma Program, New Brunswick, NJ, ¹⁶Medicine, Rheumatology, University of Chicago, Chicago, IL, ¹⁷Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ¹⁸University of Pittsburgh, Pittsburgh, PA, ¹⁹Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC, ²⁰Boston University School of Medicine, Boston, MA, ²¹Rheumatology, Tulane University School of Medicine, New Orleans, LA, ²²University of Michigan, Ann Arbor, MI, ²³Rheumatology, The George Washington University, Washington, DC, ²⁴Division of Allergy/Immunology and Rheumatology and Center for Musculoskeletal Research, School of Medicine and Dentistry, University of Rochester Medical School, Rochester, New York, USA, Rochester, NY, ²⁵Clinical Immunology & Rheum, Univ of Alabama, Birmingham, AL, ²⁶Rheumatology, Stanford University Medical Center, Stanford, CA, ²⁷Rheumatology, Columbia University, New York, NY, ²⁸David Geffen School of Medicine, UCLA, Los Angeles, CA, ²⁹Rheumatology, Henry Ford Hospital, Detroit, MI, ³⁰Rheumatology, Medical University of SC, Charleston, SC, ³¹Rheumatology, MedStar Georgetown University Hospital, Washington, DC, ³²Northwestern University, Chicago, IL, ³³Rheumatology, University California, San Francisco, San Francisco, CA, ³⁴Rheum Div/Mason F Lord, Johns Hopkins University, Baltimore, MD, ³⁵Inflammatory Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ³⁶Rheumatology, NIAMS, National Institutes of Health, Bethesda, MD
Background/Purpose: Anti-nuclear autoantibodies are a hallmark of scleroderma with anti-centromere antibody (ACA) recognizing centromeric antigens. ACA-positive patients have longstanding Raynaud’s, limited cutaneous disease and increased…
Abstract Number: 109 • 2015 ACR/ARHP Annual Meeting
Association of HLA-G and Leukocyte Immunoglobulin-like Receptor A3 Polymorphisms with the Susceptibility to Pulmonary Hyterpention in Systemic Sclerosis
Yuki Hachiya¹, Aya Kawasaki¹, Takashi Matsushita², Hiroshi Furukawa¹, Shouhei Nagaoka³, Kota Shimada⁴, Shoji Sugii⁴, Keigo Setoguchi⁵, Akira Okamoto⁶, Noriyuki Chiba⁷, Eiichi Suematsu⁸, Masao Katayama⁹, Shunsei Hirohata¹⁰, Hajime Kono¹¹, Kiyoshi Migita¹², Takayuki Sumida¹³, Shigeto Tohma¹⁴, Minoru Hasegawa¹⁵, Manabu Fujimoto¹⁶, Shinichi Sato¹⁷, Kazuhiko Takehara¹⁸ and Naoyuki Tsuchiya¹⁹, ¹Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ²Department of Dermatology, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa city, Japan, ³Rheumatology, Yokohama Minami Kyosai Hospital, Yokohama, Japan, ⁴Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Fuchu, Japan, ⁵Department of Allergy and Immunological Diseases, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan, ⁶Department of Rheumatology,, Himeji Medical Center, National Hospital Organization, Himeji, Japan, ⁷Department of Rheumatology, Morioka National Hospital, NHO, Iwate, Japan, ⁸Department of Internal Medicine and Rheumatology, National Hospital Organization, Kyushu Medical Research Center, Fukuoka, Japan, ⁹Division of Rheumatology, Department of Internal Medicine, Nagoya Medical Center, National Hospital Organization, Nagoya City, Aichi, Japan, ¹⁰Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan, ¹¹Department of Internal Medicine, Teikyo University, Tokyo, Japan, ¹²Department of Rheumatology and Clinical Research Center, Nagasaki Medical Center, Omura, Japan, ¹³Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ¹⁴Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan, ¹⁵Dermatology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan, ¹⁶Department of Dermatology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ¹⁷Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan, ¹⁸Dermatology, Department of Dermatology, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa city, Japan, ¹⁹Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
Background/Purpose: Human leukocyte antigen-G (HLA-G) is a non-classical class I molecule expressed in the immune cells, the spleen, and the lungs, and plays a key…
Abstract Number: 687 • 2013 ACR/ARHP Annual Meeting
Role Of Class II Human Leukocyte Antigens In The Progression From Early To Definite Systemic Sclerosis
Barbara Vigone¹, Alessandro Santaniello², Maurizio Marchini¹, Gaia Montanelli¹, Monica Caronni¹, Adriana Severino¹, Stefania Celeste¹ and Lorenzo Beretta³, ¹Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, ²Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, ³Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy
Background/Purpose: Criteria for the diagnosis of Early Systemic Sclerosis (EaSSc) have been formalized by LeRoy and Medsger in 2001 and later validated by Koenig et…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].